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S l e e pd i s t u r b a n c e sa r ec o m m o np r o b l e m sa ﬀecting the quality life of Parkinson’s disease (PD) patients and are often
underestimated.Thecausesofsleepdisturbancesaremultifactorialandincludenocturnalmotordisturbances,nocturia,depressive
symptoms, and medication use. Comorbidity of PD with sleep apnea syndrome, restless legs syndrome, rapid eye movement sleep
behavior disorder, or circadian cycle disruption also results in impaired sleep. In addition, the involvement of serotoninergic,
noradrenergic, and cholinergic neurons in the brainstem as a disease-related change contributes to impaired sleep structures.
Excessive daytime sleepiness is not only secondary to nocturnal disturbances or dopaminergic medication but may also be due to
independent mechanisms related to impairments in ascending arousal system and the orexin system. Notably, several recent lines
of evidence suggest a strong link between rapid eye movement sleep behavior disorder and the risk of neurodegenerative diseases
such as PD. In the present paper, we review the current literature concerning sleep disorders in PD.
1.Introduction
Parkinson’s disease (PD) is a movement disorder character-
ized by bradykinesia, resting tremors, rigidity, and impaired
postural reﬂexes, which are caused by the degeneration of
dopaminergic neurons in the substantia nigra. However, the
pathological course of PD has been recognized to be much
more extensive, involving the serotoninergic, noradrenergic,
and cholinergic systems [1]. These systems may play a role
in the development of the nonmotor symptoms commonly
observed in PD such as sleep disturbances, depression,
olfactory dysfunction, cognitive impairments, fatigue, and
autonomic dysfunctions. In a recent large study comprising
1,072 patients with PD, almost all of the patients exhibited at
least one type of nonmotor symptoms [2].
Sleepdisturbancesareamongthemostcommonnonmo-
torsymptoms,withaprevalencerangingfromapproximately
40% to 90%, and these disturbances can interfere with
patients’ quality of life [2–5]. Various factors, including noc-
turnal motor symptoms, psychiatric symptoms, dementia,
dopaminergic medications, and circadian cycle disruptions,
cause sleep disturbances [6]. Comorbidity with sleep apnea
syndrome (SAS), restless legs syndrome (RLS), and rapid
eye movement sleep behavior disorder (RBD) is often
observed, complicating the sleep disturbances related to PD.
The orexin system may be involved in PD, contributing
to the daytime sleepiness independent of impaired sleep
conditions. RBD preceding or coexisting with PD has
received attention, but whether RBD and PD are caused
by a similar neurodegenerative process remains unknown.
The evaluation and treatment of sleep disorders in PD are
of great importance because of their negative impact on
quality of life. A “sleep beneﬁt” of improved early-morning
motor function before medication intake is often reported
by some PD patients [7]. H¨ ogl et al. reported that levodopa
concentrations and polysomnographic ﬁndings were similar
between PD patients with and without the sleep beneﬁt
but that PD patients with the sleep beneﬁt exhibited a
diﬀerent response proﬁle to levodopa; the magnitude of
motor deterioration after levodopa intake was greater in PD
patients with the sleep beneﬁt than in patients without it
[8]. Subjective perceptions or sensory mechanisms may play
a role in the sleep beneﬁt in PD. In contrast, the eﬀect of
sleep deprivation on motor performance is controversial [9].
In this paper, we review and discuss the current literature
concerning sleep disorders in PD.2 Parkinson’s Disease
2.Pathophysiology of Insomnia and Excessive
DaytimeSleepiness
As a result of an examination of polysomnography (PSG)
recordings, altered sleep structure has been observed in PD,
namely,adecreaseinthequantityofnonrapideyemovement
(NREM) sleep stages 3 and 4 and REM sleep [10]. The
degeneration of cholinergic neurons in the basal forebrain
and brainstem including the pedunculopontine nucleus and
noradrenergicneuronsinthelocuscoeruleusresultsindisor-
dersofREMsleep,andalossofserotoninergicneuronsinthe
raphe nucleus is associated with a reduction in the amount
of slow-wave sleep [11]. In addition to the orexin and
histamine systems, these serotoninergic, noradrenergic, and
cholinergic neurons in brainstem serve as arousal systems
that maintain wakefulness, and disturbance of these neurons
leads to excessive daytime sleepiness. In patients with PD, a
loss of orexinergic neurons in the posterior portion of the
lateral hypothalamus [12]a n dar e d u c t i o ni nt h en u m b e r
of A10 dopaminergic neurons in the ventral tegmental
area [13]h a v eb e e ni m p l i c a t e di ni m p a i r e dw a k e f u l n e s s .
The histaminergic neurons in the hypothalamus appear
intact in patients with PD. Orexin/hypocretin may pro-
mote wakefulness by upregulating monoaminergic neuronal
populations [14]. Wake-active dopaminergic neurons in the
ventral periaqueductal gray matter have been identiﬁed [15]
but seem to be intact in patients with PD [16]. In animal
models, D2 receptors exhibit a biphasic response, with
sedating eﬀects occurring after low-dose stimulation of the
presynaptic receptors and awakening eﬀects occurring after
high-dosestimulationofthepostsynapticreceptors[17].The
ventral tegmental area and the mesolimbic and mesocortical
dopaminergic circuits are crucial sites for the action of
dopamine in the sleep-wake cycle [18]. In humans, low
doses of dopaminergic stimulation may result in sleepiness,
and high doses of stimulation may induce wakefulness,
resulting in insomnia [19]. A placebo-controlled, random-
ized, double-blind, crossover study performed in 20 healthy
volunteers using the multiple sleep latency test indicated
that low-dose ropinirole reduces the time to sleep onset
in humans [20]. By contrast, in a study of 54 consecutive
levodopa-treated patients with PD referred for sleepiness,
a positive correlation between mean daytime sleep latency
and the daily administration of levodopa was observed,
even after accounting for controlling factors, indicating that
levodopamayhavealertingeﬀectsinsomegroupsofpatients
[21]. Nevertheless, all dopaminergic drugs can have sedating
eﬀects on patients with PD, and the mechanism of this
discrepancy has not been fully elucidated [22].
3. Insomnia
Insomnia is deﬁned as a complaint of one or more of
the following symptoms: diﬃculty falling asleep, diﬃculty
staying asleep, early awakening, or nonrefreshing sleep that
occurs despite adequate opportunities for sleep. Daytime
impairments related to nighttime sleep diﬃculties have also
been reported. In a community-based survey, sleep initiation
was reported to be similar in all groups, but the PD patients
complained of greater sleep fragmentation compared with
diabetic patients or healthy control subjects [5]. In patients
with PD, sleep maintenance insomnia (diﬃculty staying
asleep) appears to be a common form of insomnia that is
frequently caused by nocturnal motor disturbances [23, 24].
Figure 1 represents the major causes of insomnia observed in
patients with PD. Insomnia is attributable to these various
causes, but the prevalence of insomnia increases as the
disease progresses along with the aging process, suggesting
that disease severity has an impact on sleep disturbances
[3, 23, 24]. Insomnia is probably correlated with depression,
disease duration [24–26], or motor symptoms [3]. In
contrast, the prevalence of insomnia was 54%–60% over an
eight-year period in a prospective study, but the data showed
no linear increase over an eight-year followup period [26].
This ﬁnding indicates that sleep disorders can occur during
an early stage of PD.
Identifying the factors contributing to insomnia can
result in an improvement in sleep. Melatonin administration
to PD patients led to a signiﬁcant improvement in subjective
sleep disturbances, sleep quantity, and daytime sleepiness
[27]. Using short-acting hypnotic drugs such as zolpidem
[28], which have less impact on muscle relaxation, is
recommended to prevent falls associated with sleep aids,
especially in elderly subjects.
3.1. Nocturnal Disturbances. Lees and colleagues [4]h a v e
reported nocturnal disturbances in 215 of 220 PD patients,
including nocturia (79%), diﬃculty turning over in bed
(65%), painful muscle cramps (55%), nightmares (48%),
limborfacialdystonia(34%),legjerks(33%),andvisualhal-
lucinations (16%). Stack and Ashburn [29] studied impaired
bed mobility in patients with PD and determined that
approximately 80% of the patients turned in bed successfully
but exhibited diﬃculty turning in bed, suggesting that
identifying the least disruptive turning strategy may be
useful.
Chaudhuri et al. [23] developed the Parkinson’s disease
sleep scale (PDSS), a visual analogue scale that includes
15 PD-related nocturnal symptoms for assessing nocturnal
disability in patients with PD. Their study showed that
patients with an advanced level of the disease had impaired
scores compared with those with early or moderate levels
of the disease. The PDSS was described in a recent review
[30] as a recommended, reliable scale, except that it may
not be suﬃcient for screening for sleep apnea, RBD, or
RLS. This scale has been validated and employed extensively
in a number of countries and was reported to exhibit
high reliability [24, 31–34]. Our multicenter study also
found more severe nocturnal disturbances in patients with
an advanced stage of PD, as measured by the PDSS,
(Hoehn & Yahr (H&Y) stage IV) compared with those
with early and moderate stages of the disease (H&Y I–III).
These disturbances were associated with disease duration,
depressive symptoms, and complications of dopaminergic
treatments (such as dyskinesia and wearing-oﬀ symptoms)
[24]. By contrast, Dhawan et al. [35] reported that nocturnalParkinson’s Disease 3
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Figure 1: The major causes of insomnia and its contributing factors. RBD: rapid eye movement sleep behavior disorder; SAS: sleep apnea
syndrome; RLS: restless legs syndrome; PLMS: periodic limb movement during sleep.
symptoms such as nocturia, nocturnal cramps, dystonia,
and tremors were observed in untreated PD patients with
short disease durations. PDSS-2, a new version of PDSS,
has been developed, and its total and three domain scores,
including disturbed sleep, motor symptoms at night, and
PD symptoms at night, have been shown to correlate with
patients’ quality of life, the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) motor scores, and disease severity in
diﬀerent patterns [36].
Nocturia is a common nighttime problem; 80% of PD
patients exhibited two or more episodes of nocturia per
night caused by overﬂow incontinence and a spastic bladder
[4]. If the nocturia is found to be related to wearing-oﬀ
symptoms, then changing medications to administer a long-
acting dopamine agonist before bedtime can be beneﬁcial.
A urologic examination is recommended because nocturia
may also be associated with the normal aging process or
underlying urological diseases.
Nocturnal motor symptoms are caused by a hypodo-
paminergic state, such as akinesia and increased tremor and
rigidity, and a hyperdopaminergic state, such as levodopa-
related dyskinesia. The inability to turn in bed and diﬃculty
in rising to pass urine during the night due to nocturnal
akinesia are signiﬁcant disabling symptoms. Increasing the
dose of a dopamine agonist or levodopa or adding these
drugstotheregimenofmedicationsadministeredatbedtime
should be considered. A double-blinded, placebo-controlled
trial with 287 PD patients demonstrated the eﬃcacy of 24-h
rotigotine on daytime motor function (UPDRS part III) and
nocturnal disabilities, as evaluated by the PDSS-2 [37]. In
addition, subcutaneous overnight apomorphine infusion led
to a dramatic reduction of nocturnal awakenings, nocturnal-
oﬀ periods, pain, dystonia, and nocturia in patients with PD
[38]. Arnulf et al. reported that high-frequency subthalamic
nucleusstimulationin10PDpatientswithinsomniareduced
nighttime akinesia by 60% and completely suppressed axial
and early-morning dystonia [39].
By contrast, a reduction in the dose of dopaminergic
drugs may be eﬀective for the symptoms associated with a
hyperdopaminergic state. If patients with frequent nocturnal
awakenings have taken amantadine or selegiline, which have
potentialalertingeﬀects,thenareductioninthedoseofthese
drugs, discontinuation of the administration of these drugs,
or a change in the time of administration of these drugs from
evening to morning may reduce the number of nocturnal
awakenings.
3.2. Assessment Tools for Sleep Disturbances in PD. PSG is
the “gold standard” method used to evaluate sleep disorders
and provides detailed information about actual sleep status,
including sleep eﬃciency, sleep latency, and sleep structure.
PSG can detect the cooccurrence of SAS, RBD, and periodic
limb movements. However, the use of PSG is limited because
of its cost and requirement for special equipment. As
an alternative, questionnaire-based sleep studies have been
widely conducted. The application of several scales for sleep
disturbances has recentlybeen reviewed[30].The Pittsburgh
Sleep Quality Index [40] is recommended to assess overall
sleep abnormalities, and the Epworth sleepiness scale (ESS)
is suggested for use in evaluating daytime sleepiness [41].
However, prior studies have reported that ESS score was
correlated with multiple sleep latencies, but the correlation
was weak and false negatives were detected, suggesting that
a normal ESS score does not exclude the sleepiness observed
in PD [21]. The Parkinson’s disease sleep scale (PDSS) [23],
a visual analogue scale including 15 PD-related nocturnal
symptoms for assessing nocturnal disability in PD, is now
a recommended, reliable scale [30]. The scale includes the
following items: overall quality of nighttime sleep (item 1),4 Parkinson’s Disease
sleep onset and maintenance insomnia (items 2 and 3),
nocturnal restlessness (items 4 and 5), nocturnal psychosis
(items 6 and 7), nocturia (items 8 and 9), nocturnal motor
symptoms (items 10-13), sleep refreshment (item 14), and
daytime dozing (item 15). For further improvement, the
PDSS-2, a modiﬁed version of the PDSS that assesses the
frequencyofnocturnalsymptomsandincludesthescreening
of SAS, has been published with an excellent level of validity
and reliability [36].
4.ExcessiveDaytimeSleepiness
After a report in 1999 stated that sudden-onset sleep episode
is associated with motor vehicle accidents in PD patients
who take nonergot dopamine agonists (either ropinirole
or pramipexole) [42], the association of excessive daytime
sleepiness (EDS) or sleep episodes with dopaminergic med-
ications has become a focus of attention. Approximately
15%–50% of PD patients have been reported to show
EDS [43–45]. A high Epworth sleepiness scale (ESS) score,
male gender status, longer disease duration, and high-
disease severity have also been observed to be associated
with EDS [43, 44, 46]. Similar to the insomnia observed
in patients with PD, multiple factors are associated with
EDS: impaired arousal systems in addition to the disease
process, dopaminergic medication, nocturnal disturbances,
and concurrent primary sleep disorders such as SAS, RBD,
and RLS are thought to be contributing factors. In addition,
narcolepsy-like symptoms have been observed in patients
with PD. Daytime sleepiness or sleep episodes exhibiting
a short sleep latency, short sleep onset REM period, and
decreased orexin levels are independent of the patients’
nighttime sleep conditions. These symptoms are similar
to those observed in narcolepsy, which is a sleep disorder
characterized by severe daytime sleepiness and caused by
loss of orexin neurons. However, cataplexy is lacking in
patients with PD [47], and the role of orexin levels in
PD patients with EDS is still controversial. Studies in PD
patients with EDS have not observed a reduction in orexin
concentrations in the cerebrospinal ﬂuid [48, 49]. However,
while markedly decreased orexin levels in the hypothalamus
and a loss of orexin neurons have been observed in PD
patientsandweresigniﬁcantlycorrelatedwithclinicaldisease
progression, no description was provided for EDS [12, 50].
The lumbar cerebrospinal ﬂuid may not reﬂect the orexin
cell loss reported in the hypothalamus of patients with PD.
Further research is needed to determine whether a decrease
in the number of orexin neurons in the hypothalamus or
other systems, in addition to orexin dysfunction, accounts
for EDS in PD patients. Additional work is also required to
determine whether decreased orexin levels reﬂect disease-
related changes or secondary, compensatory changes that
result from dopaminergic dysfunction [51, 52].
Several studies have demonstrated that taking dopamine
agonists or levodopa is associated with increased daytime
sleepiness in patients with PD [43, 44, 46, 53, 54]; however,
several other studies have failed to conﬁrm this signiﬁcant
association [55, 56]. To date, whether speciﬁc dopamine
agonists are associated with sleepiness is still unclear [43, 44,
54]. Sudden onset sleep episodes while driving have been
reported in 3.8%–22.8% of PD patients and are associated
with a high score on the ESS [43, 46, 56]. This ﬁnding
suggests that PD patients with high ESS scores are at risk for
experiencing sleep episodes while driving.
5. Comorbid Sleep Disorders
5.1. Rapid Eye Movement Sleep Behavior Disorder. Rapid eye
movement sleep behavior disorder (RBD) is characterized
by a loss of muscle atonia during REM sleep that results in
dream-enacting behavior, which often leads to injury to the
individual or bed partner [57]. RBD tends to aﬀect older
individuals and has a higher prevalence in males [58].
Lesions of the locus coeruleus perialpha in cats and the
sublaterodorsal nucleus in rats have been suggested to cause
REM sleep without atonia and with complex movements
[59, 60]. Involvement of subcoeruleus-coeruleus complex
was found in cases with incidental Lewy body disease
(preclinical stages of PD) [61]. This brain region may be
crucial for RBD pathophysiology in addition to the cholin-
ergic nuclei, pedunculopontine nucleus, and laterodorsal
tegmentalnucleus,whichplayaroleinregulatingREMsleep.
A ﬂip-ﬂop switch model for the control of REM sleep has
been proposed: GABAergic REM-on neurons located in the
sublaterodorsalnucleusinhibitGABAergicREM-oﬀneurons
located in the ventrolateral periaqueductal gray matter and
lateral pontine tegmentum, and vice versa [62].
RBDwasconsideredtobeanidiopathic,isolateddisorder
until a study in 1996 by Schenck demonstrated that 38% of
29 patients with idiopathic RBD developed PD after a mean
followup of 3.7 ± 1.4y e a r s[ 63]. Subsequently, a positive
association has emerged between RBD and neurodegener-
ative disorders, particularly synucleinopathies such as PD,
multiple system atrophy, and dementia with Lewy bodies
[58, 64, 65]. Early manifestations of PD preceding the onset
of typical motor symptoms, such as impaired visual and
olfactory discrimination, cardiac sympathetic denervation,
and cognitive impairment, have been observed in idiopathic
RBD patients [66–70]. As a possible prodromal phase of
neurodegenerative diseases, a diagnosis of RBD is crucial
for early intervention to treat neurodegenerative disorders.
Therefore, to establish an accurate diagnosis, a quantitative
visual scoring of the electromyographic (EMG) data in
REM sleep may be necessary [71]. In a recent report,
RBD preceded the onset of synucleinopathies by up to 50
years [72], indicating that if idiopathic RBD patients lived
long enough, the underlying cause of the neurodegenerative
disease would be unveiled [73].
Recently, Iranzo et al. [74] conducted a study measuring
PSG at baseline and after a mean followup of ﬁve years; this
study revealed that excessive tonic and phasic EMG activity
occurs during REM sleep and is increased over time in
patients with RBD. This ﬁnding suggests that an underlying
progressive process aﬀects the brainstem in patients with
R B D .E v e nt h o u g ha sm a n ya sh a l fo fR B Dp a t i e n t sw i l l
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observed in the incidence rates of PD development, and no
method exists to predict which patients will develop PD. We
cannot currently predict why some idiopathic RBD patients
develop PD and others do not. However, a recent study
by Postuma et al. has helped elucidate this subject. Their
results indicate that in subjects with idiopathic RBD initially
free of neurodegenerative disease, the severity of the REM
atonia loss on the baseline PSG ﬁndings can predict PD
development [75].
In terms of the comorbidity of PD and RBD, PD patients
with RBD exhibited a predominantly nontremor pheno-
type, an increased frequency of falls, and a poor response
to dopaminergic medications, which were associated with
orthostatichypotensionandimpaired colorvision.However,
overall disease severity, quantitative motor testing, and
motorcomplicationsdidnotdiﬀerbetweenPDpatientswith
RBD and those without RBD [76, 77]. Interestingly, restored
motor control (movements, speech, and facial expressions)
has been observed during REM sleep with enacted dreams in
PD patients who had RBD [78].
RBD can be triggered by antidepressants, such as
tricyclics, selective serotonin reuptake inhibitors, and
serotonin-norepinephrine reuptake inhibitors; by beta-
blockers; by states of barbiturate and alcohol withdrawal
[79]; however, whether the subjects who develop RBD
are susceptible to drugs or whether they have underlying
diseases has not been fully elucidated. Clonazepam (0.5 to
1.5mg) at bedtime is eﬀective for decreasing the frequency
and severity of RBD; however, it has little eﬀect on EMG
tone [80]. Melatonin has been indicated to ameliorate RBD
symptoms [81] and improve EMG tone during REM sleep
[82]. Levodopa and pramipexole also reduce the clinical
manifestations of RBD [80], although in a prospective
study of 11 consecutive PD patients with RBD, pramipexole
improved parkinsonism but did not modify RBD [83]. The
administration of the herbal medication Yi-Gan San at 2.5g
three times a day, alone or in conjunction with 0.25mg
clonazepam, has been reported to be eﬀective in treating
RBD[84].However,therehavebeennorandomized,double-
blind, placebo-controlled trials on the treatment for RBD in
the PD population.
RBD may be a prodrome of neurodegenerative disorders,
including PD, and this notion is a topic of great interest. As a
result, the following questions are under investigation: what
factors can determine who will develop neurodegenerative
disorders? who will remain free of symptoms during life?
whatneuroprotectivestrategyiseﬀectiveforpatientswhoare
susceptibletoneurodegenerativedisorders?andwhenshould
this strategy be employed?
5.2. Restless Legs Syndrome. Restless legs syndrome (RLS)
and PD are considered to share pathophysiological char-
acteristics, given that both neurological disorders exhibit
favorable responses to dopaminergic medications; however,
RLS usually responds to lower doses than those required
for PD. In addition, several studies have demonstrated a
higher rate of comorbidity of RLS and PD compared with
the prevalence of idiopathic RLS in the general population
[3, 85], while other studies have reported no diﬀerence in
the prevalence of RLS when comparing PD patients with
the general population [86, 87]. However, one should note
that daytime dopaminergic medications for PD may unmask
subclinical RLS by augmentation, resulting in an increased
prevalence of RLS in PD [88]. Patients with PD may not
report RLS symptoms unless asked because they regard RLS
as a part of the PD symptom complex [89].
In PD patients, nonmotor symptoms related to non-
dopaminergic systems, such as cognitive impairments, auto-
nomic dysfunction, depression, and sleepiness, but not
motor symptoms were observed to be associated with RLS
[90]. G´ omez-Esteban et al. [85]r e p o r t e dah i g hp r e v a l e n c e
of RLS (21.9%) in PD patients but determined no diﬀerence
in disease severity, UPDRS scores, or quality of life between
PD groups with or without RLS. Caution must be taken for
RLS mimics in PD. Peralta et al. [91] described a positive
associationbetweenmotorﬂuctuations,thewearing-oﬀphe-
nomenon, and RLS symptoms in PD patients but suggested
that oﬀ-period restlessness can be an “RLS mimic.”
Autopsy studies have revealed increased substantia nigra
(SN) iron levels in PD patients [92] and decreased SN iron
levels in RLS patients [93] .Ar e c e n ts t u d yb yK w o ne t
al. [94] employing transcranial sonography demonstrated
no signiﬁcant diﬀerences in SN echogenicity, which is
considered to reﬂect the quantity of tissue iron, between PD
patients with and without RLS, whereas the idiopathic RLS
patients demonstrated signiﬁcant SN hypoechogenicity. This
ﬁnding suggests that the pathogenesis of PD with RLS and
idiopathic RLS may involve diﬀerent mechanisms.
Caﬀeine, alcohol, and several medications, including
antihistamines, dopamine antagonists, tricyclic antidepres-
sants, and serotoninergic reuptake inhibitors, can exacerbate
RLS [95]. Although the pathophysiology of RLS is not fully
understood, a central dopaminergic dysfunction has been
implicated based on the ﬁndings that dopamine agonists
relieve patients’ symptoms and that decreased dopamine
D2 receptor binding is observed in the striata of RLS
patients by SPECT [96]. The A11 hypodopaminergic theory,
which involves spinal cord positive feedback mechanisms
that mediate dopamine, has been proposed using an animal
model [97]. Dysfunctions of the A11 dopaminergic dien-
cephalospinal pathways, which innervate the preganglionic
sympathetic neurons and dorsal horn of the spinal cord,
lead to an increased sympathetic drive that results in
the occurrence of RLS [98]. An iron deﬁciency can also
contribute to impairments in dopamine signaling in the
brain. Low iron and ferritin levels in the cerebrospinal
ﬂuid have been observed in patients with RLS [99, 100].
Iron replacement therapy should be considered when serum
levels of ferritin are below 50μg/L. When taken at bedtime,
dopamineagonistssuchaspramipexoleandropinirolearean
eﬀective treatment for RLS.
RLS and PD may share a pathogenesis; however, the
pathogenic link between RLS and PD should be investigated
further.
5.3. Sleep Apnea Syndrome. Previous studies have reported a
highincidenceofsleepapneasyndrome(SAS)inPDpatients6 Parkinson’s Disease
(approximately 20%–60%) compared with age- and sex-
matched control patients [21, 101, 102]. In these studies, the
body mass index of patients with PD was similar to or even
lower than that of control patients, suggesting that upper
airway muscle dysfunction caused by nocturnal akinesia or
dyskinesia of the respiratory muscle may play a role in the
development of obstructive sleep apnea (OSA) in PD [103].
By contrast, a study measuring PSG over three consecutive
nights found that the apnea-hypopnea index (AHI) was not
diﬀerent between PD patients and control patients and that
the rate of OSA in PD patients was similar to that observed
in the general population [104]. Another study reported that
sleep apnea, deﬁned as an AHI >5, was less frequent in
the PD group compared with an in-hospital control group
who exhibited daytime sleepiness (27% versus 40%) and
that daytime sleepiness was caused by other, nonapneic,
mechanisms [105]. The relationship between OSA and PD
requires further investigation.
Nocturnal stridor, a life-threatening event caused by
vocal cord abductor dysfunction, has been observed in
patients with PD but occurs more frequently in patients with
multiple system atrophy [106]. It is important to screen for
vocal cord abductor dysfunction using laryngoscopy during
sleep. Adequate treatments, including continuous positive
airway pressure therapy, noninvasive positive pressure venti-
lation, or tracheotomy, can prevent sudden death in patients.
5.4. Circadian Rhythm Sleep Disorders. In PD, circadian
rhythm during sleep, blood pressure, heart rate, and levels
of cortisol and melatonin hormones may be altered, possibly
due to autonomic dysfunction, changes in sleep structure,
and dopaminergic treatments [107–110]. In addition, PD
patients with dementia may exhibit sundowning [111].
The suprachiasmatic nucleus (SCN) is the crucial center
responsible for generating the circadian rhythm. The SCN
is included in the paraventricular zone of the hypotha-
lamus, which is a component of the central autonomic
network(CAN)thatcontrolsautonomicfunctionsinastate-
dependent manner [112]. The SCN seems to be intact in PD
patients, but the reported involvement of the hypothalamus
and brainstem in PD patients [113, 114]a p p e a r st ob e
associated with the CAN.
In animal models of PD, signiﬁcant decreases in midline
estimating statistics of rhythm and phase advances were
observed for heart rate, locomotor activity, and core body
temperature (CBT) [115]. Pierangeli et al. [116]h a v e
demonstrated that a nocturnal fall in CBT was attenuated in
multiple system atrophy compared with PD. Similarly, in a
smallcohortstudyofprogressivesupranuclearpalsypatients,
a decreased circadian amplitude of CBT was observed
compared with that of PD patients [117]. In our previous
study of 24 nondepressed PD patients and six depressed
PD patients, we demonstrated that nondepressed patients
exhibited a circadian rhythm of CBT, but two out of six
of the depressed patients exhibited an infradian rhythm as
a predominant rhythm in CBT. The remaining depressed
patients demonstrated a decreased circadian amplitude of
CBT compared with that of the nondepressed PD patients
[118]. Our results suggest that PD patients with depression
can exhibit circadian rhythm abnormalities compared with
PD patients without depression. Further research, including
a larger number of PD patients and control subjects, is
needed to conﬁrm this ﬁnding.
5.5. Depression. The reported prevalence of depression in
PD patients varies, ranging from 2.7% to 89% [119].
This variation may be due to the population studied or
methods employed for diagnosis. Depression is associated
with sleep disorders, nocturnal motor symptoms, and poor
quality of life [120–123]. Depression is also related to
motor ﬂuctuations, such as wearing-oﬀ symptoms [124].
In a recent randomized, double-blinded, placebo-controlled
trial, pramipexole, which has a higher aﬃnity for D3 than
D2 or D4 receptors, signiﬁcantly improved the depressive
symptoms of PD patients, suggesting that this drug is
useful for treating depression in addition to the selective
serotonin reuptake inhibitors and tricyclic antidepressants
often used for treating depression [125]. Hence, identifying
and treating depression or depressive symptoms can be
beneﬁcial in ameliorating sleep disorders and nocturnal
motor dysfunctions in PD patients.
6. Conclusion
Sleep disorders can occur in the early stages of PD and
worsen as the disease progresses. The worsening of sleep
disturbancesoccursinamannersimilartotheprogressionof
motor dysfunctions, cognitive impairments, and depression,
which supports the idea that complex mechanisms and
impairments of the arousal system and sleep structure
play a role. Sleep disturbances can be underestimated if
the patients, their families, and their physicians do not
investigate the possibility of impaired sleep.
Active intervention for sleep disturbance is of great
importance, as sleep disturbances can signiﬁcantly impair
the quality of life of patients with PD.
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